Einzeltreffer — DigiBib

Background: Viral infections can cause significant morbidity in cystic fibrosis (CF). The current Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic could therefore have a serious impact on the health of people with CF (pwCF).

Methods: We used the 38-country European Cystic Fibrosis Society Patient Registry (ECFSPR) to collect case data about pwCF and SARS-CoV-2 infection.

Results: Up to 30 June 2020, 16 countries reported 130 SARS-CoV-2 cases in people with CF, yielding an incidence of 2.70/1000 pwCF. Incidence was higher in lung-transplanted patients (n=23) versus non-transplanted patients (n=107) (8.43 versus 2.36 cases/1000). Incidence was higher in pwCF versus the age-matched general population in the age groups <15, 15-24, and 25-49 years (p<0.001), with similar trends for pwCF with and without lung transplant. Compared to the general population, pwCF (regardless of transplantation status) had significantly higher rates of admission to hospital for all age groups with available data, and higher rates of intensive care, although not statistically significant. Most pwCF recovered (96.2%), however 5 died, of whom 3 were lung transplant recipients. The case fatality rate for pwCF (3.85%, 95% CI: 1.26-8.75) was non-significantly lower than that of the general population (7.46%; p=0.133).

Conclusions: SARS-CoV-2 infection can result in severe illness and death for pwCF, even for younger patients and especially for lung transplant recipients. PwCF should continue to shield from infection and should be prioritized for vaccination.

Competing Interests: Declaration of Competing Interest Dr. Naehrlich reports that he has received institutional fees for site participation in clinical trials from Vertex Pharmaceuticals and Boehringer Ingelheim; Dr. Orenti has nothing to disclose; Dr. Dunlevy reports institutional grants from Chiesi, during the conduct of the study; Dr. Kasmi has nothing to disclose; Dr. Harutyunyan has nothing to disclose; Dr. Pfleger has nothing to disclose; Dr. Bobrovnichy has nothing to disclose;Dr. Keegan has nothing to disclose; Dr. Daneau has nothing to disclose; Dr. Petrova has nothing to disclose; Dr. Bambir has nothing to disclose; Dr. Vukić Dugac has nothing to disclose; Dr. Tješić-Drinković has nothing to disclose; Dr. Yiallouros has nothing to disclose; Dr. Drevinek reports personal fees from Vertex Pharmaceuticals, outside the submitted work; Prof. Milan Macek reports grants from Vertex Pharmaceuticals, outside the submitted workr r; Mrs. Bilkova has nothing to disclose; Dr. Olesen has nothing to disclose; Dr. Burgel reports personal fees from Astra-Zeneca, personal fees from Boehringer Ingelheim, personal fees from Chiesi, personal fees from GSK, personal fees from Insmed, personal fees from Novartis, personal fees from Pfizer, grants and personal fees from Vertex, personal fees from Zambon, outside the submitted work; Dr. Corvol has nothing to disclose; Ms. Lemmonier has nothing to disclose; Dr. Parulava has nothing to disclose; Dr. Hatziagorou has nothing to disclose; Dr. Diamantea has nothing to disclose; Dr. Párniczky has nothing to disclose; G. Fletcher has nothing to disclose; Prof. McKone reports travel support from A Menarini, speaker fees from Roche Pharmaceuticals, consultancy fees from Insmed, consultancy fees from Janssen Pharmaceuticals, grants to institution and consultancy fees from Vertex, outside the submitted work; Dr. Mei-Zahav has nothing to disclose; Dr. Padoan has nothing to disclose; Dr. Salvatore has nothing to disclose; Dr. Colombo has nothing to disclose; Dr. Aleksejeva has nothing to disclose; Dr. Malakauskas has nothing to disclose; Dr. Schlesser has nothing to disclose; Dr. Fustik has nothing to disclose; Dr. Turcu has nothing to disclose; V. Gulmans has nothing to disclose; D. Zomer-van Ommen has nothing to disclose; Dr. Wathne has nothing to disclose; Dr. Bakkeheim has nothing to disclose; Dr. Wozniacki has nothing to disclose; Dr. Pereira has nothing to disclose; Dr. Pop has nothing to disclose; Dr. Kondratyeva has nothing to disclose; Dr. Amelina has nothing to disclose; Dr. Zhekaite has nothing to disclose; Dr. O. Simonova has nothing to disclose; Dr. Kashirskaya has nothing to disclose; Dr. Rodic has nothing to disclose; Dr. Kayserova has nothing to disclose; Dr. Krivec has nothing to disclose; Dr. Mondejar-Lopez has nothing to disclose; Dr. Pastor-Vivero has nothing to disclose; Dr. de Monestrol reports grants from Vertex, outside the submitted work; Dr. Lindblad has nothing to disclose; Dr. Dogru has nothing to disclose; Dr. Gokdemir has nothing to disclose; Dr. Pekcan has nothing to disclose; Dr. Makukh has nothing to disclose; Dr. Brownlee has nothing to disclose; Ms. Cosgriff has nothing to disclose; Mr. McClenaghan has nothing to disclose; Dr. Carr reports personal fees from Chiesi Pharmaceuticals, personal fees and non-financial support from Vertex, personal fees from Zambon, personal fees from Insmed, outside the submitted work; Dr. Lammertyn has nothing to disclose; Dr. Zolin has nothing to disclose; Ms.. Fox reports grants from ECFS, during the conduct of the study; Mr Krasnyk has nothing to disclose; Mrs. Van Rens has nothing to disclose; Dr. van Koningsbruggen-Rietschel reports grants and personal fees from Algipharma (HORIZON2020), personal fees from Deutsches Zentrum für Infektionsforschung, personal fees from Antabio, personal fees from Proteostasis, personal fees from Roche, personal fees from Vertex, outside the submitted work; Dr. Jung reports grants from Chiesi Pharmaceuticals, during the conduct of the study.

Titel:	Incidence of SARS-CoV-2 in people with cystic fibrosis in Europe between February and June 2020.
Autor/in / Beteiligte Person:	Naehrlich, L ; Orenti, A ; Dunlevy, F ; Kasmi, I ; Harutyunyan, S ; Pfleger, A ; Keegan, S ; Daneau, G ; Petrova, G ; Tješić-Drinković, D ; Yiallouros, P ; Bilkova, A ; Olesen, HV ; Burgel, PR ; Parulava, T ; Diamantea, F ; Párniczky, A ; McKone, EF ; Mei-Zahav, M ; Salvatore, M ; Colombo, C ; Aleksejeva, E ; Malakauskas, K ; Schlesser, M ; Fustik, S ; Turcu, O ; Zomer-van Ommen, D ; Wathne, AS ; Woźniacki, Ł ; Pereira, L ; Pop, L ; Kashirskaya, N ; Rodić, M ; Kayserova, H ; Krivecs, U ; Mondejar-Lopez, P ; de Monestrol I ; Dogru, D ; Makukh, H ; Cosgriff, R ; van Koningsbruggen-Rietschel S ; Jung, A
Link:	Full Text Finder (Volltext) View record from ScienceDirect (Volltext)
Zeitschrift:	Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, Jg. 20 (2021-07-01), Heft 4, S. 566-577
Veröffentlichung:	Amsterdam ; New York : Elsevier, c2002-, 2021
Medientyp:	academicJournal
ISSN:	1873-5010 (electronic)
DOI:	10.1016/j.jcf.2021.03.017
Schlagwort:	Adolescent Adult COVID-19 diagnosis COVID-19 therapy Child Child, Preschool Critical Care Cystic Fibrosis mortality Cystic Fibrosis therapy Europe epidemiology Female Hospitalization Humans Incidence Infant Infant, Newborn Lung Transplantation Male Middle Aged Registries Retrospective Studies Young Adult COVID-19 epidemiology Cystic Fibrosis complications
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Corporate Authors: European Cystic Fibrosis COVID project group Publication Type: Journal Article; Observational Study Language: English [J Cyst Fibros] 2021 Jul; Vol. 20 (4), pp. 566-577. <i>Date of Electronic Publication: </i>2021 Apr 18. MeSH Terms: COVID-19 / epidemiology ; Cystic Fibrosis / complications ; Adolescent ; Adult ; COVID-19 / diagnosis ; COVID-19 / therapy ; Child ; Child, Preschool ; Critical Care ; Cystic Fibrosis / mortality ; Cystic Fibrosis / therapy ; Europe / epidemiology ; Female ; Hospitalization ; Humans ; Incidence ; Infant ; Infant, Newborn ; Lung Transplantation ; Male ; Middle Aged ; Registries ; Retrospective Studies ; Young Adult Contributed Indexing: Investigator: V Bobrovnichy, Belarusian Republic Children's Center of Pulmonology and Cystic Fibrosis, Pulmonary Department, 3rd City Children's Clinical Hospital, Minsk, Belarus.; I Bambir, University Hospital Centre Zagreb, Cystic Fibrosis Centre - Paediatrics and Adults, Zagreb, Croatia.; AD Vukic, University Hospital Centre Zagreb, Cystic Fibrosis Centre - Paediatrics and Adults, Zagreb, Croatia.; P Drevinek, Department of Medical Microbiology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic.; MM Jr, Department of Biology and Medical Genetics, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic.; H Corvol, Sorbonne Université, Centre de Recherche Saint-Antoine, Inserm UMR_S938, Assistance Publique-Hôpitaux de Paris, Hôpital Trousseau, Pediatric Pulmonology Department and Cystic Fibrosis Center, Paris, France.; L Lemonnier-Videau, Vaincre la Mucoviscidose, Paris, France.; E Hatziagorou, Cystic Fibrosis Unit, Hippokration General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.; G Fletcher, The Cystic Fibrosis Registry of Ireland, Dublin, Ireland.; R Padoan, Cystic Fibrosis Regional Support Centre, Department of Paediatrics, University of Brescia, Brescia, Italy.; V Gulmans, Dutch Cystic Fibrosis Foundation (NCFS), Baarn, The Netherlands.; E Bakkeheim, Norwegian Resource Centre for Cystic Fibrosis, Oslo University Hospital, Oslo, Norway.; E Kondratyeva, Clinical research department of cystic fibrosis 'Research Centre for Medical Genetics', Moscow, Russian Federation.; E Amelina, Norwegian Resource Centre for Cystic Fibrosis, Oslo University Hospital, Oslo, Norway.; E Zhekaite, Cystic Fibrosis Department, Pulmonology Research Institute of the Federal Medical and Biological Agency of Russia, Moscow, Russian Federation.; O Simonova, Center for rare disease National Medical Research Center for Children's Health, Moscow, Russia; Morozov State Pediatric Teaching Hospital, Moscow Healthcare Department; I.M. Sechenov First Moscow State Medical University (Sechenov University), Healthcare Ministry of Russia, Moscow, Russian Federation.; MD Pastor-Vivero, Pediatric Pneumology and Cystic Fibrosis Unit, Osakidetza, Hospital Universitario Cruces, Bizkaia, Spain.; A Lindblad, Gothenburg CF Centre, Queen Silvia Children's Hospital, The Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.; Y Gökdemir, Division of Pulmonology, Marmara University Faculty of Medicine, Istanbul, Turkey.; S Pekcan, Division of Pediatric Pulmonolgy, Meram Faculty of Medicine, Necmettin Erbakan University, Konya, Turkey.; K Brownlee, Cystic Fibrosis Trust, London, UK.; E McClenaghan, Cystic Fibrosis Trust, London, UK.; S Carr, Sciensano, Epidemiology and public health, Health services research, Brussels, Belgium.; E Lammertyn, Cystic Fibrosis Europe, Brussels; Association Muco A.S.B.L. - Mucovereniging V.Z.W., Brussels, Belgium.; A Zolin, Department of Clinical Sciences and Community Health, Laboratory of Medical Statistics, Epidemiology and Biometry G. A. Maccacaro, University of Milan, Milan, Italy.; A Fox, European Cystic Fibrosis Society Patient Registry, Karup, Denmark.; M Krasnyk, European Cystic Fibrosis Society Patient Registry, Karup, Denmark.; J Van Rens, European Cystic Fibrosis Society Patient Registry, Karup, Denmark. ; Keywords: Covid-19; Cystic fibrosis; Epidemiology; Europe; Incidence; SARS-CoV-2 Entry Date(s): Date Created: 20210521 Date Completed: 20210910 Latest Revision: 20210910 Update Code: 20231215 PubMed Central ID: PMC8053246

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

Incidence of SARS-CoV-2 in people with cystic fibrosis in Europe between February and June 2020.